Hairy cell leukaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:16 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hairy cell leukaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Obinutuzumab, Vemurafenib, and Cobimetinib for Hairy Cell Leukemia in Patients Previously Treated with Purine Analogs or Unfit for Chemotherapy https://clinicaltrials.eu/trial/study-of-obinutuzumab-vemurafenib-and-cobimetinib-for-hairy-cell-leukemia-in-patients-previously-treated-with-purine-analogs-or-unfit-for-chemotherapy/ Wed, 29 Apr 2026 15:04:02 +0000 https://clinicaltrials.eu/trial/study-of-obinutuzumab-vemurafenib-and-cobimetinib-for-hairy-cell-leukemia-in-patients-previously-treated-with-purine-analogs-or-unfit-for-chemotherapy/ This clinical trial is focused on studying a type of blood cancer called Hairy Cell Leukemia (HCL). The study involves patients who have either been previously treated with certain drugs called purine analogs or are not suitable for chemotherapy. The trial will use a combination of three medications: Obinutuzumab, Vemurafenib, and Cobimetinib. These medications are being tested together to see how well they work in treating HCL, especially in patients with a specific genetic change known as the BRAF-V600E mutation.

The purpose of the study is to understand how effective these drugs are in fighting the leukemia. The trial is organized into different groups, where patients will receive the medications in a step-by-step manner. Obinutuzumab is given as an infusion, which means it is administered directly into the bloodstream through a vein. Vemurafenib and Cobimetinib are taken as tablets by mouth. The study will observe how patients respond to these treatments over time.

Participants in the study will be monitored for any side effects and how well the leukemia responds to the treatment. The trial aims to gather information on the safety and effectiveness of the drug combination, including how long patients remain free from the disease and their overall survival. This research is important for developing better treatment options for people with Hairy Cell Leukemia.

]]>